ストックスクリーナーアプリを入手
8.21
0.85%
-0.07
前日終値:
$8.28
開ける：
$8.13
24時間の取引高:
261.71K
Relative Volume:
0.13
時価総額：
$37.58M
収益：
-
当期純損益:
$-54.66M
株価収益率:
-0.4305
EPS:
-19.0729
ネットキャッシュフロー:
$-49.98M
1週間 パフォーマンス:
+40.58%
1か月 パフォーマンス:
+24.77%
6か月 パフォーマンス:
-37.33%
1年 パフォーマンス:
+59.49%
1日の値動き範囲:
$7.54
$8.39
1週間の範囲:
$5.91
$8.72
52週間の値動き範囲:
$1.55
$15.74
Nextcure Inc Stock (NXTC) Company Profile
名前
Nextcure Inc
セクター
電話
240-399-4900
住所
9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE, MD
Compare NXTC vs VRTX, REGN, ARGX, RVMD, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NXTC
Nextcure Inc
|
8.21 | 37.40M | 0 | -54.66M | -49.98M | -19.07 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Nextcure Inc Stock (NXTC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-07 | アップグレード | Ladenburg Thalmann | Neutral → Buy |
| 2022-11-04 | ダウングレード | Ladenburg Thalmann | Buy → Neutral |
| 2022-03-01 | 開始されました | Ladenburg Thalmann | Buy |
| 2021-03-05 | アップグレード | Truist | Hold → Buy |
| 2021-01-15 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2020-07-16 | アップグレード | The Benchmark Company | Hold → Buy |
| 2020-07-13 | ダウングレード | ROTH Capital | Buy → Neutral |
| 2020-07-13 | ダウングレード | SunTrust | Buy → Hold |
| 2020-06-01 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2020-06-01 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2020-05-26 | 開始されました | JMP Securities | Mkt Outperform |
| 2020-03-24 | 開始されました | The Benchmark Company | Buy |
| 2020-03-02 | 開始されました | ROTH Capital | Buy |
| 2020-01-13 | 開始されました | SunTrust | Buy |
| 2019-12-05 | 開始されました | Needham | Buy |
| 2019-11-26 | 開始されました | BTIG Research | Buy |
| 2019-07-09 | 開始されました | BofA/Merrill | Buy |
| 2019-06-03 | 開始されました | Morgan Stanley | Overweight |
| 2019-06-03 | 開始されました | Piper Jaffray | Overweight |
すべてを表示
Nextcure Inc (NXTC) 最新ニュース
Ikarian Capital discloses 9.99% NextCure (NXTC) stake including large warrant position - Stock Titan
NextCure (NXTC) gains 15.8% beneficial owner in ADAR1 Capital and manager - Stock Titan
NextCure Inc (NASDAQ: NXTC) Stock Price, News & Analysis - Kalkine
NextCure (NXTC): Squadron funds and partners disclose 1.6% equity stake - Stock Titan
Affinity Asset Advisors discloses 6.4% NextCure (NXTC) stake via stock and warrants - Stock Titan
NextCure stock rating reiterated at Buy by H.C. Wainwright - Investing.com
Major Former Stakeholder Makes a Significant Move in NextCure Stock - TipRanks
Adage Capital files Schedule 13G showing 7.67% NextCure (NXTC) ownership - Stock Titan
Simcere Zaiming sells $184,800 of NextCure stock - Investing.com
Simcere Zaiming sells $184,800 of NextCure stock By Investing.com - Investing.com Canada
Simcere group (NXTC) trims NextCure stake, ends 10% beneficial ownership - Stock Titan
RTW Biotech's Avere to go public in US in reverse merger with NextCure - London South East
NextCure - thepharmaletter.com
NextCure (NXTC) plans reverse merger with Avere and $820M financings - Stock Titan
Xcellon Acquires 40,000 Sq ft Maryland Facility from NextCure to Deliver a cGMP-Ready CRDMO for ADCs - BioBuzz
Xcellon Biologics Acquires GMP Manufacturing Facility from NextCure, Becoming an End-to-End CRDMO for Next-Generation Bioconjugates and Complex Biologics - The Manila Times
Avere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001 - Nasdaq
NextCure Inc (NXTC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
NextCure reports Q2 2026 net loss $14.9M, cash $20.1M as it pursues merger with Avere - tradingview.com
NextCure, Inc. Q2 2026: Net income $(14.9)M, EPS $(2.80) — 10-Q Summary - tradingview.com
NextCure (NASDAQ: NXTC) details Avere merger, $320M financing and going concern risk - Stock Titan
NextCure (Nasdaq: NXTC) details Q2 2026 loss and Avere merger - Stock Titan
NextCure Provides Business Update and Reports Second Quarter 2026 Financial Results - The Manila Times
NextCure Q2 FY26 net loss narrows to $14.89 million; R&D expenses drop to $7.43 million - Bitget
NextCure (NXTC) details two-step Avere merger plan and upcoming Form S-4 - Stock Titan
Form 4 NextCure Inc For: 4 August By Investing.com - Investing.com UK
Adar1 Capital Management buys $1.6m in NextCure (NXTC) shares - Investing.com
Adar1 Capital Management buys $1.6m in NextCure (NXTC) shares By Investing.com - Investing.com India
ADAR1 Capital Management reports NextCure common share purchase worth $3.59 million - Bitget
ADAR1-managed funds buy 329,153 shares of NextCure (NXTC) - Stock Titan
NextCure Inc expected to post a loss of $1.93 a shareEarnings Preview - TradingView
NextCure, Inc. Revenue Breakdown – NASDAQ:NXTC - tradingview.com
Form 4 NextCure Inc For: 29 July By Investing.com - Investing.com South Africa
Adar1 capital management increases NextCure (NXTC) stake by $87,712 - Investing.com Canada
NXTC|NextCure Inc|Price:5.200|Chg%:+0.960 - TradingKey
NextCure Inc (NXTC) Cash Flow - TradingKey
NextCure Inc (NXTC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
NextCure Inc (NXTC) Balance Sheet - TradingKey
NextCure Inc (NXTC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
NextCure Inc (NXTC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
NXTC|NextCure Inc|Price:5.090|Chg%:+0.850 - TradingKey
NextCure Inc (NXTC) Income Statement - TradingKey
NextCure, Inc. Revenue Breakdown – MUN:2US0 - TradingView
NextCure Inc. (NXTC) Edges Higher as Biotech Sentiment Shifts — Resistance Test LoomsLong Term Entry Picks - dars.gov.et
NextCure Inc (NXTC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Gibson Dunn guides biotech reverse merger - ICLG
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--VEEE, NXTC, TCBK, and FHB - Finansavisen
NextCure Inc. (NXTC) Q1 2026 Earnings: EPS Beats Estimates, Stock Declines on Pre-Revenue StatusROIC Trend Report - dars.gov.et
Are CRNX, VEEE, NXTC, TCBK Obtaining Fair Deals for their Shareholders? - Finansavisen
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger—VEEE, NXTC, TCBX, and FHB - Carroll County Mirror-Democrat
NextCure announces reverse merger with privately held Avere - MSN
Nextcure Inc (NXTC) 財務データ
収益
当期純利益
現金流量
EPS
0.52%
0.07%
大文字化:
|
ボリューム (24 時間):